

What we claim is:

1. A composition of matter comprising, as active agents,  
an adjuvant-effective amount of at least one sialidase  
and (2) an unrelated antigenic vaccine which gives rise  
to antibodies against an organism whose portal of  
entry, site of reproduction or site of disease  
causation is the mucosa, in a pharmaceutically  
acceptable carrier.
2. A composition of claim 1 wherein the carrier is a solid  
support.
3. A composition of claim 1 which is a liquid.
4. A composition of claim 1 which is a powder.
5. A composition of claim 1 which is in capsule or tablet  
form.
6. A composition of claim 1 containing, additionally,  
anti-CD43 antibodies.
7. A composition of claim 1 which is a gel, a cream or a  
suppository.
8. A method of enhancing immune response in mammal by  
administration to the mucosa of an immune enhancing  
effective amount of sialidases in a pharmaceutically  
accepted carrier in conjunction with a antigenic  
vaccine.
9. A method of claim 8 wherein sialidase is administered  
in the form of drops or a spray.
10. A method of claim 8 wherein sialidase is administered  
in powder form.

11. A method of claim 8 wherein sialidase is administered on a solid support.
12. A method of claim 8 wherein sialidase is administered orally.
13. A method of claim 8 wherein sialidase is administered in animal feed.
14. A method of claim 8 wherein sialidase is administered in conjunction with an anti-CD4 antibody.
15. A method of claim 14 wherein the anti-CD4 antibody is an anti-CD43 antibody.